BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28077607)

  • 1. Anatomy of Mdm2 and Mdm4 in evolution.
    Tan BX; Liew HP; Chua JS; Ghadessy FJ; Tan YS; Lane DP; Coffill CR
    J Mol Cell Biol; 2017 Feb; 9(1):3-15. PubMed ID: 28077607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MDM2 gene family.
    Mendoza M; Mandani G; Momand J
    Biomol Concepts; 2014 Mar; 5(1):9-19. PubMed ID: 25372739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of MDM2 family genes.
    Momand J; Villegas A; Belyi VA
    Gene; 2011 Oct; 486(1-2):23-30. PubMed ID: 21762762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.
    Coffill CR; Lee AP; Siau JW; Chee SM; Joseph TL; Tan YS; Madhumalar A; Tay BH; Brenner S; Verma CS; Ghadessy FJ; Venkatesh B; Lane DP
    Genes Dev; 2016 Feb; 30(3):281-92. PubMed ID: 26798135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.
    Marcar L; Ihrig B; Hourihan J; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Hupp TR; Meek DW
    PLoS One; 2015; 10(5):e0127713. PubMed ID: 26001071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
    Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
    Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
    Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
    Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of MDM4 (MDMX) function by p76(MDM2): a new facet in the control of p53 activity.
    Giglio S; Mancini F; Pellegrino M; Di Conza G; Puxeddu E; Sacchi A; Pontecorvi A; Moretti F
    Oncogene; 2010 Nov; 29(44):5935-45. PubMed ID: 20697359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2-MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance.
    Moscetti I; Teveroni E; Moretti F; Bizzarri AR; Cannistraro S
    Int J Nanomedicine; 2016; 11():4221-9. PubMed ID: 27621617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.
    Chee SMQ; Wongsantichon J; Siau J; Thean D; Ferrer F; Robinson RC; Lane DP; Brown CJ; Ghadessy FJ
    PLoS One; 2017; 12(12):e0189379. PubMed ID: 29228061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of kidney development by the Mdm2/Mdm4-p53 axis.
    El-Dahr S; Hilliard S; Saifudeen Z
    J Mol Cell Biol; 2017 Feb; 9(1):26-33. PubMed ID: 28096292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the p53-MDM2 pathway.
    Åberg E; Saccoccia F; Grabherr M; Ore WYJ; Jemth P; Hultqvist G
    BMC Evol Biol; 2017 Aug; 17(1):177. PubMed ID: 28774266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
    Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
    Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network.
    Hoffman Y; Pilpel Y; Oren M
    J Mol Cell Biol; 2014 Jun; 6(3):192-7. PubMed ID: 24868102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
    Qi DL; Cobrinik D
    Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
    Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
    Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G
    Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.